Axonics® to report 2019 fourth quarter and full-year financial results and host a conference call on march 4

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“snm”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the 2019 fourth quarter and full year, and provide an update on u.s. launch activities after the market closes on wednesday, march 4, 2020. in conjunction with the release, the company will host a conference call with the investment community that same day at 4:30 p.m. eastern time to discuss the financial results and current business developments. interested parties may access the live call via telephone by dialing (866) 687-5771 (u.s.) or (409) 217-8725 (international) and using passcode 8582626. a live webcast of the call may be accessed by visiting the events & presentations page of the investor relations section of the company's website at ir.axonics.com. a replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website for 90 days. about axonics modulation technologies, inc. axonics, based in irvine, calif., has developed and is commercializing novel implantable snm devices for patients with urinary and bowel dysfunction. these conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. overactive bladder affects an estimated 87 million adults in the u.s. and europe. another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. snm therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. reimbursement coverage is well established in the u.s. and europe. the axonics system is the first rechargeable snm system approved for sale in the world, and the first to gain full-body mri conditional labeling. for more information, visit the company’s website at www.axonics.com.
AXNX Ratings Summary
AXNX Quant Ranking